Displaying drugs 14151 - 14175 of 14723 in total
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
25CN-NBOH (N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine) is a newly developed selective 5-HT2A agonist. It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion . It was discovered in 2014 at the University of Copenhagen.
Experimental
Matched Description: … It has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects …
Carbon black
Produced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment with demonstrated adverse effects on pulmonary function. Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue and has been linked to carcinogenicity.[A263406, A263411, A263416]
Investigational
Matched Description: … inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and …
CP-271485
Experimental
Albendazole oxide
Experimental
Daxalipram
Experimental
2-[4-(2,4-Dichlorophenoxy)Phenoxy]Propanoic Acid
Experimental
(R)-Atenolol
Experimental
CHS-828
CHS-828 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
7-Deazaguanine
Experimental
Asimadoline
Asimadoline is a proprietary small molecule therapeutic, originally discovered by Merck KGaA of Darmstadt, Germany. Asimadoline was originally developed to treat peripheral pain such as arthritis. Asimadoline is an orally administered agent that acts as a kappa opioid receptor agonist. It has shown encouraging clinical efficacy for the treatment of...
Investigational
Matched Description: … has shown encouraging clinical efficacy for the treatment of IBS in a barostat study in IBS patients and …
Displaying drugs 14151 - 14175 of 14723 in total